High Insider Ownership Growth Companies To Watch In November 2024
editorial-team@simplywallst.com (Simply Wall St)
4 min read
As global markets navigate the impact of rising U.S. Treasury yields and a cautious economic outlook, investors are increasingly looking towards growth companies with high insider ownership as potential opportunities. In such volatile conditions, stocks with significant insider ownership may signal confidence from those who know the company best, making them intriguing options for those seeking resilient growth prospects.
Top 10 Growth Companies With High Insider Ownership
Overview: Shanghai Aiko Solar Energy Co., Ltd. is involved in the research, manufacture, and sale of crystalline silicon solar cells, with a market cap of CN¥21.98 billion.
Operations: The company's revenue is primarily derived from its activities in the research, production, and distribution of crystalline silicon solar cells.
Insider Ownership: 18.2%
Revenue Growth Forecast: 51.8% p.a.
Shanghai Aiko Solar Energy Ltd. is forecasted to grow revenue significantly at 51.8% per year, outpacing the Chinese market's average growth rate. Despite trading well below its estimated fair value and relative industry peers, recent financial performance shows challenges with a net loss of CNY 2.83 billion for the nine months ended September 2024, compared to a net income of CNY 1.89 billion in the previous year, indicating potential risks amidst high growth expectations.
Overview: VAT Group AG, with a market cap of CHF 11.03 billion, develops and supplies vacuum valves and related products across Switzerland, Europe, the United States, Asia, and other international markets.
Operations: The company's revenue is primarily derived from its Valves segment, which generated CHF 783.51 million, and its Global Service segment, contributing CHF 163.83 million.
Insider Ownership: 10.2%
Revenue Growth Forecast: 17.5% p.a.
VAT Group is poised for substantial earnings growth, with forecasts indicating a 21.8% annual increase, surpassing the Swiss market average. Despite this positive outlook, its share price has been highly volatile recently. The company's stock is trading at 31.3% below its estimated fair value, suggesting potential upside for investors. While revenue growth of 17.5% per year exceeds the market rate, it remains below the high-growth threshold of 20%.
Overview: Porton Pharma Solutions Ltd. manufactures and sells small molecule active pharmaceutical ingredients, dosage forms, and biologics to pharmaceutical companies in China, the United States, and Europe with a market cap of CN¥9.93 billion.
Operations: The company generates revenue through the production and distribution of active pharmaceutical ingredients, dosage forms, and biologics to clients in China, the United States, and Europe.
Insider Ownership: 26.7%
Revenue Growth Forecast: 20.6% p.a.
Porton Pharma Solutions is expected to achieve profitability within three years, with revenue growth anticipated at 20.6% annually, outpacing the Chinese market average. However, recent earnings reports indicate a challenging period, with a net loss of CNY 206.43 million for the first nine months of 2024 compared to a profit last year. Despite these setbacks and high share price volatility, no substantial insider trading activity has been reported in the past three months.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SHSE:600732 SWX:VACN and SZSE:300363.
